Cómo citar
Osorio, J. H., Aguirre, C. A., & Valencia, M. H. (2008). Implicaciones metabólicas y clínicas del uso de los inhibidores de la 3-hidroxi-3-metilglutaril coenzima a reductasa para el control de la hipercolesterolemia. Biosalud, 7, 115–129. Recuperado a partir de https://revistasojs.ucaldas.edu.co/index.php/biosalud/article/view/5837


José Henry Osorio
Universidad de Caldas. Manizales
César Augusto Aguirre
Universidad de Caldas. Manizales
Mauricio Hernando Valencia
Universidad de Manizales


La hipercolesterolemia es importante como factor de riesgo para enfermedad cardiovascular. El tratamiento con estatinas de la hipercolesterolemia, se basa en la inhibición competitiva de la 3-hidroxi-3-metilglutaril coenzima A reductasa (HMG-CoA), que cataliza un paso limitante de la biosintesis del colesterol. La presente revisión analiza la literatura científica relacionada con el metabolismo del colesterol y las implicaciones clínico-metabólicas del uso de estatinas para el control de colesterol.

Franssen R, Monajemi H, Stroes ES, Kastelein JJ. Obesity and dyslipidemia. Endocrinol Metab Clin North Am. 2008;37(3):623-33.

Razani B, Chakravarthy MV, Semenkovich CF.Insulin resistance and atherosclerosis. Endocrinol Metab Clin North Am. 2008;37(3):603-21.

Nicholls SJ. HDL: still a target for new therapies? Curr Opin Investig Drugs. 2008 Sep;9(9):950-6.

Amarenco P. Lipid lowering and recurrent stroke: a definitive answer? Int J Stroke. 2007;2(2):111-3.

Brodsky JL, Fisher EA. The many intersecting pathways underlying apolipoprotein B secretion and degradation. Trends Endocrinol Metab. 2008;19(7):254-9.

Bordoni A, Di Nunzio M, Danesi F, Biagi PL. Polyunsaturated fatty acids: From diet to binding to ppars and other nuclear receptors. Genes Nutr. 2006;1(2):95-106.

Barter P, Ginsberg HN. Effectiveness of combined statin plus omega-3 fatty acid therapy for mixed dyslipidemia. Am J Cardiol. 2008;102(8):1040-5.

Ailhaud G. Omega-6 fatty acids and excessive adipose tissue development. World Rev Nutr Diet. 2008;98:51-61.

Boden G. Obesity and free fatty acids. Endocrinol Metab Clin North Am. 2008 Sep;37(3):635-46.

Vine DF, Glimm DR, Proctor SD. Intestinal lipid transport and chylomicron production: possible links to exacerbated atherogenesis in a rodent model of the metabolic syndrome. Atheroscler Suppl. 2008;9(2):69-76.

Vourvouhaki E, Dedoussis GV. Cholesterol ester transfer protein: a therapeutic target in atherosclerosis? Expert Opin Ther Targets. 2008;12(8):937-48.

Kratz M. Dietary cholesterol, atherosclerosis and coronary heart disease. Handb Exp Pharmacol. 2005;(170):195-213.

Blain JF, Poirier J. Cholesterol homeostasis and the pathophysiology of Alzheimer’s disease. Expert Rev Neurother. 2004;4(5):823-9.

Mouritsen OG, Zuckermann MJ. What’s so special about cholesterol? Lipids. 2004;39(11):1101-13.

Backes JM, Gibson CA. Effect of lipid-lowering drug therapy on small-dense low-density lipoprotein. Ann Pharmacother. 2005;39(3):523-6.

Brunner EJ, Rees K, Ward K, Burke M, Thorogood M. Dietary advice for reducing cardiovascular risk. Cochrane Database Syst Rev. 2007.

DeFaria Yeh D, Freeman MW, Meigs JB, Grant RW. Risk factors for coronary artery disease in patients with elevated high-density lipoprotein cholesterol. Am J Cardiol. 2007; 99(1):1-4.

Hachem SB, Mooradian AD. Familial dyslipidaemias: an overview of genetics, pathophysiology and management. Drugs. 2006;66(15):1949-69.

Blank RC, Brunton S. Managing multiple cardiovascular risk factors. J Fam Pract. 2008;57(3 Suppl Managing):S13-20.

Toth PP, Davidson MH. High-dose statin therapy: benefits and safety in aggressive lipid lowering. J Fam Pract. 2008;57(5 Suppl High-Dose):S29-36.

Grigore L, Norata GD, Catapano AL. Combination therapy in cholesterol reduction: focus on ezetimibe and statins. Vasc Health Risk Manag. 2008;4(2):267-78.

Kratz M. Dietary cholesterol, atherosclerosis and coronary heart disease. Handb Exp Pharmacol. 2005;(170):195-213.

Grundy SM. Metabolic syndrome: therapeutic considerations Handb Exp Pharmacol. 2005;(170):107-33.

von Eckardstein A. Risk factors for atherosclerotic vascular disease. Handb Exp Pharmacol. 2005;(170):71-105.

Bocksch W, Fateh-Moghadam S, Huehns S, Schartl M. Influence of different lipid-lowering strategies on plaque volume and plaque composition in patients with coronary artery disease: role of intravascular ultrasound imaging. Kidney Blood Press Res. 2005;28(5-6):290-4.

Steiner G. Lipid lowering in the patients with prediabetes/metabolic syndrome: what is the evidence? Curr Opin Lipidol. 2008;19(6):585-91.

Tomillero A, Moral MA.Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2008;30(7):543-88.

Guymer RH, Dimitrov PN, Varsamidis M, Lim LL, Baird PN, Vingrys AJ, Robman L. Can HMG Co-A reductase inhibitors (“statins”) slow the progression of age-related macular degeneration? The agerelated maculopathy statin study (ARMSS). Clin Interv Aging. 2008;3(3):581-93.

Koh KK, Quon MJ, Waclawiw MA.Are statins effective for simultaneously treating dyslipidemias and hypertension? Atherosclerosis. 2008 ;196(1):1-8.

Szárszoi O, Malý J, Ostádal P, Netuka I, Besík J, Kolár F, Ostádal B. Effect of acute and chronic simvastatin treatment on post-ischemic contractile dysfunction in isolated rat heart. Physiol Res. 2008;57(5):793-6.

Mandell BF.A drug, a concept, and a clinical trial on trial. Cleve Clin J Med. 2008 ;75(7):470.

Petty D, Lloyd D. Can cheap generic statins achieve national cholesterol lowering targets. J Health Serv Res Policy. 2008;13(2):99-102.

Fox KM, Gandhi SK, Ohsfeldt RL, Davidson MH. Comparison of low-density lipoprotein cholesterol reduction after switching patients on other statins to rosuvastatin or simvastatin in a real-world clinical practice setting. Am J Manag Care. 2007;13 Suppl 10:S270-5.

Newman CB, Palmer G, Silbershatz H, Szarek M. Safety of atorvastatin derived from analysis of 44 completed trials in 9416 patients. Am J Cardiol 2003;92:670-6.

Pasternak RC, Smith SC, Bairey-Merz CN, et al. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. Stroke 2002;33: 2337-41.

Nakad A, Bataille I, Hamoir V, Sempoux C, Horsmans Y. Atorvastatin-induced acute hepatitis with absence of cross-toxicity with simvastatin. Lancet, 1999, 353: 1763-1764.

Dresser GK, Spence JD, Bailey D.G. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome p450 3A4 inhibition. Clin. Pharmacokinet., 2000, 38: 41-57.

Tonolo G, Melis MG, Formato M, et al. Additive effects of simvastatin beyond its effects on LDL cholesterol in hypertensive type 2 diabetic patients. Eur J Clin Invest 2000;30:980-7.

Kostapanos M, Milionis H, Gazi I, et al. Rosuvastatin increases alpha-1 microglobulin urinary excretion in patients with primary dyslipidemia. J Clin Pharmacology 2006;46(11):1337-43.

van Zyl-Smit R, Firth JC, Duffield M, Marais AD. Renal tubular toxicity of HMG-CoA reductase inhibitors. Nephrol Dial Transplant 2004;19:3176-9.

Tonolo G, Ciccarese M, Brizzi P, et al. Reduction of albumin excretion rate in normotensive microalbuminuric type 2 diabetic patients during long-term simvastatin treatment. Diabetes Care 1997;20:1891-5.

Vidt DG, Cressman MD, Harris S, Pears JS, Hutchinson HG. Rosuvastatin-induced arrest in progression of renal disease. Cardiology 2004;102:52-60.

El-Hajj II, Mourad FH, Shabb NS, Barada KA. Atorvastatin-induced severe gastric ulceration: a case report. World J Gastroenterol 2005;11:3159-60.

Batey RG, Harvey M. Cholestasis associated with the use of pravastatin sodium. Med J Aust 2002;176:561.

Yoshida EM, Levin A. Lovastatin and cholestasis. CMAJ 1993;148:374.

Rea WE, Durrant DC, Boldy DA. Ulcerative colitis after statin treatment. Postgrad Med J 2002;78:286-7.

Miltiadous G, Anthopoulou A, Elisaf M. Acute pancreatitis possibly associated with combined salicylate and atorvastatin therapy. JOP 2003;4:20-1.

Tysk C, Al-Eryani AY, Shawabkeh AA. Acute pancreatitis induced by fluvastatin therapy. J Clin Gastroenterol 2002;35:406-8.

Pezzilli R, Ceciliato R, Corinaldesi R, Barakat B. Acute pancreatitis due to simvastatin therapy: increased severity after rechallenge. Dig Liver Dis 2004;36:639-40.

Johnson JL, Loomis IB. A case of simvastatin-associated pancreatitis and review of statin-associated pancreatitis. Pharmacotherapy 2006;26:414-22.

Singh S, Nautiyal A, Dolan JG. Recurrent acute pancreatitis possibly induced by atorvastatin and rosuvastatin. Is statin induced pancreatitis a class effect? JOP 2004;5:502-4.

Lons T, Chousterman M. Simvastatin: a new drug responsible for acute pancreatitis? Gastroenterol Clin Biol 1991;15:93-4.

Belaiche G, Ley G, Slama JL. Acute pancreatitis associated with atorvastatin therapy. Gastroenterol Clin Biol 2000;24:471-2.

Anagnostopoulos GK, Tsiakos S, Margantinis G, Kostopoulos P, Arvanitidis D. Acute pancreatitis due to pravastatin therapy. JOP 2003;4:129-32.

Bousquet E, Amar J, Salvador M, Chamontin B. Cataract and simvastatin: case report. Therapie 1998;53:505-507.

Schlienger RG, Haefeli WE, Jick H, Meier CR. Risk of cataract in patients treated with statins. Arch Intern Med 2001;161:2021-6.

Smeeth L, Hubbard R, Fletcher AE. Cataract and the use of statins: a case–control study. QJM 2003;96:337-43.

Klein BE, Klein R, Lee KE, Grady LM. Statin use and incident nuclear cataract. JAMA 2006;295:2752-8.

FraunfelderFW. Ocular hemorrhage possibly the result of HMG-CoA reductase inhibitors. J Ocul Pharmacol Ther 2004;20:179-82.

Liberopoulos EN, Mikhailidis DP. Could statins be useful in the treatment of patients with migraine? Headache 2006;46:672-5.

Ramsey CS, Snyder QC. Altitude-induced migraine headache secondary to pravastatin: case report. Aviat Space Environ Med 1998;69:603-6.

Ahmad S. Lovastatin and peripheral neuropathy. Am Heart J 1995;130:1321.

Gaist D, Garcia Rodriguez LA, Huerta C, Hallas J, Sindrup SH. Are users of lipid-lowering drugs at increased risk of peripheral neuropathy? Eur J Clin Pharmacol 2001;56:931-3.

Rajabally YA, Varakantam V, Abbott RJ. Disorder resembling Guillain–Barre syndrome on initiation of statin therapy. Muscle Nerve 2004;30:663-6.

Gaist D, Jeppesen U, Andersen M, et al. Statins and risk of polyneuropathy: a case–control study. Neurology 2002;58:1333-7.

Corrao G, Zambon A, Bertu L, et al. Lipid lowering drugs prescription and the risk of peripheral neuropathy: an exploratory case–control study using automated databases. J Epidemiol Commun Health 2004;58:1047-51.

Anderson JL, Muhlestein JB, Bair TL, et al. Do statins increase the risk of idiopathic polyneuropathy? Am J Cardiol 2005;95: 1097-9.

Stewart RA, Sharples KJ, North FM, et al. Long-term assessment of psychological well-being in a randomized placebo-controlled trial of cholesterol reduction with pravastatin. The LIPID Study Investigators. Arch Intern Med 2000;160:3144-52.

Boumendil E, Tubert-Bitter P. Depression-induced absenteeism in relation to antihyperlipidemic treatment: a study usingGAZELcohort data. Epidemiology 1995;6:322- 5.

Rosenson RS, Goranson NL. Lovastatin-associated sleep and mood disturbances. Am J Med 1993;95:548-9.

Ehrenberg BL, Lamon-Fava S, Corbett KE, et al. Comparison of the effects of pravastatin and lovastatin on sleep disturbance in hypercholesterolemic subjects. Sleep 1999;22:117-21.

Gregoor PJ. Atorvastatin may cause nightmares. BMJ 2006;332:950.

Vgontzas AN, Kales A, Bixler EO, Manfredi RL, Tyson KL. Effects of lovastatin and pravastatin on sleep efficiency and sleep stages. Clin Pharmacol Ther 1991;50:730-7.

Orsi A, Sherman O,Woldeselassie Z. Simvastatin-associated memory loss. Pharmacotherapy 2001;21:767-9.

Bollen EL, Gaw A, Buckley BM. Statin therapy and the prevention of dementia. Arch Neurol 2001;58:1023-4.

Etminan M, Gill S, Samii A. The role of lipid-lowering drugs in cognitive function: a meta-analysis of observational studies. Pharmacotherapy 2003;23:726-30.

Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-78.

GurmHS, Hoogwerf B. The Heart Protection Stydy: high-risk patients benefit from statins, regardless of LDL-C level. Cleve Clin J Med 2003;70:991-7.

Liebhaber MI, Wright RS, Gelberg HJ, Dyer Z, Kupperman JL. Polymyalgia, hypersensitivity pneumonitis and other reactions in patients receiving HMG-CoA reductase inhibitors: a report of ten cases. Chest 1999;115:886-9.

Lantuejoul S, Brambilla E, Brambilla C, Devouassoux G. Statininduced fibrotic nonspecific interstitial pneumonia. Eur Respir J 2002;19:577-80.

Segal AS. Alopecia associated with atorvastatin. Am J Med 2002;113:171.

Krasovec M, Elsner P, Burg G. Generalized eczematous skinrash possibly due to HMG-CoA reductase inhibitors. Dermatology1993;186:248-52.

Mehregan DR, Mehregan DA, Pakideh S. Cheilitis due to treatmentwith simvastatin. Cutis 1998;62:197-8.

Pua VS, Scolyer RA, Barnetson RS. Pravastatin-induced lichenoiddrug eruption. Australas J Dermatol 2006;47:57-9.

Adcock BB, Hornsby LB, Jenkins K. Dermographism: an adverseeffect of atorvastatin. J Am Board Fam Pract 2001;14:148-51.

Anliker MD, Wuthrich B. Chronic urticaria to atorvastatin. Allergy 2002;57:366.

Pfeiffer CM, Kazenoff S, Rothberg HD. Toxic epidermal necrolysisfrom atorvastatin. JAMA 1998;279:16134.

Bruckert E, Giral P, Heshmati HM, Turpin G. Men treated with hypolipidaemic drugs complain more frequently of erectile dysfunction. J Clin Pharm Ther 1996;21:89-94.

Hildebrand RD, Hepperlen TW. Lovastatin and hypospermia. Ann Inter Med 1990; 120:970.

Rizvi K, Hampson JP, Harvey JN. Do lipid-lowering drugs cause erectile dysfunction? A systematic review. Fam Pract 2002;19:95-8.

Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.

Aerts J, Karmochkine M, Raguin G. Gynecomastia due to pravastatin. Presse Med 1999;28:787.

de Graaf L, Brouwers AH, Diemont WL. Is decreased libido associated with the use of HMG-CoAreductase inhibitors? Br J Clin Pharmacol 2004;58:326-8.

Elahi MM, Cagampang FR, Anthony FW, Curzen N, Ohri SK, Hanson MA. Statin treatment in hypercholesterolemic pregnant mice reduces cardiovascular risk factors in their offspring. Hypertension. 2008 Apr;51(4):939-44. Epub 2008 Feb 19.

Andrade SE, Raebel MA, Brown J, Lane K, Livingston J, Boudreau D, Rolnick SJ, Roblin D, Smith DH, Dal Pan GJ, Scott PE, Platt R. Outpatient use of cardiovascular drugs during pregnancy. Pharmacoepidemiol Drug Saf. 2008 Mar;17(3):240-7.

Miedema MD, Conover CA, MacDonald H, Harrington SC, Oberg D, Wilson D, Henry TD, Schwartz RS.Pregnancy-associated plasma protein-A elevation in patients with acute coronary syndrome and subsequent atorvastatin therapy. Am J Cardiol. 2008 1;101(1):35-9.

Kazmin A, Garcia-Bournissen F, Koren G. Risks of statin use during pregnancy: a systematic review. J Obstet Gynaecol Can. 2007;29(11):906-8.

Ofori B, Rey E, Bérard A.Risk of congenital anomalies in pregnant users of statin drugs. Br J Clin Pharmacol. 2007;64(4):496-509.

Bell DS. Diabetes: a cardiac condition manifesting as hyperglycemia. Endocr Pract. 2008;14(7):924-32.

Adeghate E. Visfatin: structure, function and relation to diabetes mellitus and other dysfunctions. Curr Med Chem. 2008;15(18):1851-62.

Gorkin JU, Watson K, Knopp RH. Strategies for reducing cardiovascular risk in patients with hypertriglyceridemia. J Fam Pract. 2007 ;56(8 Suppl Strategies):S1-7; quiz S8.

Lennernas H. Clinical pharmacokinetics of atorvastatin. Clin Pharmacokinet 2003;42: 1141-1160.

Brown MS,Goldstein J L. A receptor-mediated pathway for cholesterol homeostasis. Science 1986;232:34-47.

Hare C B, Vu M P, Grunfeld,C, Lampiris H W. Simvastatin-nelfinavir interaction implicated in rhabdomyolysis and death. Clin Infect Dis 2002;35:e111-e112.

Peters T K, Mehra M, Muratti EN. Efficacy and safety of fluvastatin in hypertensive patients. An analysis of a clinical trial database. Am J Hypertens 1993;6:340S-345S.

Gadbut A P, Caruso A P, Galper,JB. Differential sensitivity of C2–C12 striated muscle cells to lovastatin and pravastatin. J Mol Cell Cardiol 1995;27:2397-2402.

Transon C, Leemann T, Vogt N, Dayer P. In vivo inhibition profile of cytochrome P45OTB (CYP2C9) by (+/-)-fluvastatin. Clin. Pharmacol Ther 1995;58:412-417.

Transon C, Leemann T, Dayer P. In vitro comparative inhibition profiles of major human drug metabolising cytochrome P450 isozymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitors. Eur J Clin Pharmacol 1996;50:209-215.

Corsini A, Bellosta,S, Baetta R, Fumagalli R, Paoletti R,Bernini, F. New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol Ther 1999; 84:413-428.

Sirtori CR. Tissue selectivity of hydroxymethylglutaryl coenzyme A (HMG CoA) reductase inhibitors. Pharmacol Ther 1993;60:431-459.

Miles L, Miles M V, Tang PH, Horn P S,Wong B L, DeGrauw, TJ, et al. Muscle Coenzyme Q: a potential test fot mitochondrial activity and redox status. Pediatr Neurol 2005;32:318-324.

Flint OP, Masters BA, Gregg RE, Durham SK. Inhibition of cholesterol synthesis by squalene synthase inhibitors does not induce myotoxicity in vitro. Toxicol Appl Pharmacol 1997;145:91-98.

Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA 2003;289:1681-1690.

Kajinami K, Masuya H, Hoshiba Y, Takeda K, Sato R, Okabayashi M, et al. Statin response and pharmacokinetics variants. Expert Opin Pharmacother 2005;6:1291-1297.


Los datos de descargas todavía no están disponibles.
Sistema OJS - Metabiblioteca |